Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rankning i aktier #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Aktiekurs
$0.16328419
Marknadsvärde
$204.14K
Förändring (1 dag)
4.35%
Förändring (1 år)
102.45%
Land
GB
Handel Fusion Antibodies plc (FAB)

Kategori

EPS för Fusion Antibodies plc (FAB)
EPS per September 2025 TTM: $-0.02
Enligt Fusion Antibodies plcs senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $-0.02. Vid slutet av 2024 hade bolaget ett EPS på $-0.05, en minskning jämfört med EPS från 2023 som var $-0.12.
EPS-historik för Fusion Antibodies plc från 2013 till 2026
EPS vid slutet av varje år
År EPS Ändra
2026 (TTM) $-0.02 -3.00%
2025 $-0.02 -54.35%
2024 $-0.05 -58.93%
2023 $-0.12 102.30%
2022 $-0.06 -59.83%
2021 $-0.15 286.73%
2020 $-0.04 -47.38%
2019 $-0.07 22.53%
2018 $-0.06 -994.12%
2017 $0.01 -90.93%
2016 $0.08 -1,393.10%
2015 $-0.01 -31.76%
2014 $-0.01 -73.60%
2013 $-0.03 0.00%
EPS för liknande företag eller konkurrenter
Företag EPS EPS-differens Land
$3.62 -18,771.65%
DK
$15.47 -79,842.27%
US
$43.12 -222,368.04%
US
$9.62 -49,691.75%
BE
$38.32 -197,625.77%
NL